WuXi AppTec Pays $135 Million to Acquire Oxgene, a Gene Therapy CDMO

WuXi AppTec, a China-global CRO/CMO, paid $135 million to acquire Oxgene, a UK CDMO that develops scaleable gene technologies to develop cell and gene therapies. Previously, WuXi 's gene therapy unit licensed Oxgene's novel TESSA technology for adeno-associated viral (AAV) manufacturing and XLenti stable solutions. WuXi found the technology a big improvement over the competition and wanted to invest in Oxgene, but ended up acquiring the entire company. Oxgene will become part of WuXi Advanced Therapies, WuXi 's year-old cell and gene therapy Contract Testing, Development and Manufacturing Organization unit. More details.... Share this with colleagues: // //
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.